The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Cannabinoids and Pain: New Insights From Old Molecules
Open accessAbstract
Cannabis has been used for medicinal purposes for thousands of years. The prohibition of cannabis in the middle of the 20th century has arrested cannabis research. In recent years there is a growing debate about the use of cannabis for medical purposes. The term 'medical cannabis' refers to physician-recommended use of the cannabis plant and its components, called cannabinoids, to treat disease or improve symptoms. Chronic pain is the most commonly cited reason for using medical cannabis. Cannabinoids act via cannabinoid receptors, but they also affect the activities of many other receptors, ion channels and enzymes. Preclinical studies in animals using both pharmacological and genetic approaches have increased our understanding of the mechanisms of cannabinoid-induced analgesia and provided therapeutical strategies for treating pain in humans. The mechanisms of the analgesic effect of cannabinoids include inhibition of the release of neurotransmitters and neuropeptides from presynaptic nerve endings, modulation of postsynaptic neuron excitability, activation of descending inhibitory pain pathways, and reduction of neural inflammation. Recent meta-analyses of clinical trials that have examined the use of medical cannabis in chronic pain present a moderate amount of evidence that cannabis/cannabinoids exhibit analgesic activity, especially in neuropathic pain. The main limitations of these studies are short treatment duration, small numbers of patients, heterogeneous patient populations, examination of different cannabinoids, different doses, the use of different efficacy endpoints, as well as modest observable effects. Adverse effects in the short-term medical use of cannabis are generally mild to moderate, well tolerated and transient. However, there are scant data regarding the long-term safety of medical cannabis use. Larger well-designed studies of longer duration are mandatory to determine the long-term efficacy and long-term safety of cannabis/cannabinoids and to provide definitive answers to physicians and patients regarding the risk and benefits of its use in the treatment of pain. In conclusion, the evidence from current research supports the use of medical cannabis in the treatment of chronic pain in adults. Careful follow-up and monitoring of patients using cannabis/cannabinoids are mandatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 1×
“…of the International Association for the Study of Pain provided “a weak recommendation against the use of cannabinoids in neuropathic pain, mainly because of negative results, potential misuse, abuse, diversion and long-term mental health risks particularly in susceptible” (Finnerup et al., 2015).”
BackgroundAdverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
DSM-5 criteria for substance use disorders: recommendations and rationale
Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060782 · Cited by 1,622
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Cannabis sativa: The Plant of the Thousand and One Molecules
Andre, C. M., Hausman, J.-F., & Guerriero, G. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00019 · Cited by 1,544
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A. M., Selley, D. E., Parsons, L. H., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.129 · Cited by 934
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Interdisciplinary chronic pain management: Past, present, and future.
Gatchel, R. J., McGeary, D. D., McGeary, C. A., & Lippe, B. (2014) · American Psychologist · doi:10.1037/a0035514 · Cited by 856
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Paracetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
CB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 619
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Anandamide and vanilloid TRPV1 receptors
Ross, R. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705467 · Cited by 604
The CB2 receptor and its role as a regulator of inflammation
Turcotte, C., Blanchet, M.-R., Laviolette, M., & Flamand, N. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2300-4 · Cited by 588
US epidemiology of cannabis use and associated problems
Hasin, D. S. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.198 · Cited by 578
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
Moulin, D., Boulanger, A., Clark, A., Clarke, H., Dao, T., Finley, G., Furlan, A., Gilron, I., Gordon, A., Morley-Forster, P., et al. (2014) · Pain Research and Management · doi:10.1155/2014/754693 · Cited by 529
Ibrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521
Phytochemistry of Cannabis sativa L.
ElSohly, M. A., Radwan, M. M., Gul, W., Chandra, S., & Galal, A. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_1 · Cited by 521
Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., & Di Marzo, V. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.02.074 · Cited by 491
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479
Ohlsson, A., Lindgren, J.-E., Wahlen, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. (1980) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1980.181 · Cited by 475
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
An update on PPAR activation by cannabinoids
O'Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 449
Allosteric Modulation of the Cannabinoid CB1 Receptor
Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 443
Wade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr581oa · Cited by 441
Portenoy, R. K., Ganae-Motan, E. D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., & Fallon, M. T. (2012) · The Journal of Pain · doi:10.1016/j.jpain.2012.01.003 · Cited by 420
Zhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., & O'Donnell, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02704.x · Cited by 419
Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016) · The Journal of Pain · doi:10.1016/j.jpain.2016.03.002 · Cited by 412
An analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411 · cited 1×
“The effect of THC and other cannabinoids acting at CB1 receptors on motor activity in animals may easily be misinterpreted as pain-suppressing behavior (Meng et al., 1998).”
BackgroundBehavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
Martin, B. R., Compton, D. R., Thomas, B. F., Prescott, W. R., Little, P. J., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R., & Susan J., W. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90349-7 · Cited by 409
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406
Neugebauer, V. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-46450-2_13 · Cited by 399
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397
Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395
Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., & James, I. (2001) · Pain · doi:10.1016/s0304-3959(00)00474-7 · Cited by 379
The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012) · Pain · doi:10.1016/j.pain.2012.04.020 · Cited by 375
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
Clapper, J. R., Moreno-Sanz, G., Russo, R., Guijarro, A., Vacondio, F., Duranti, A., Tontini, A., Sanchini, S., Sciolino, N. R., Spradley, J. M., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2632 · Cited by 346
Do medical marijuana laws reduce addictions and deaths related to pain killers?
Powell, D., Pacula, R. L., & Jacobson, M. (2018) · Journal of Health Economics · doi:10.1016/j.jhealeco.2017.12.007 · Cited by 345
Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women
Wall, M. E., Sadler, B. M., Brine, D., Taylor, H., & Perez-Reyes, M. (1983) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1983.179 · Cited by 345
Huang, S. M., Bisogno, T., Petros, T. J., Chang, S. Y., Zavitsanos, P. A., Zipkin, R. E., Sivakumar, R., Coop, A., Maeda, D. Y., De Petrocellis, L., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107351200 · Cited by 339
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Zajicek, J. P. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.070136 · Cited by 335
Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069401 · Cited by 328
Cannabinoid–Opioid Interaction in Chronic Pain
Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E., & Benowitz, N. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.188 · Cited by 319
Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain
Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2012.10.009 · Cited by 314
Herzberg, U., Eliav, E., Bennett, G. J., & Kopin, I. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13308-5 · Cited by 307
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide
Chemin, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7033 · Cited by 299
The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?
Lambert, D., Vandevoorde, S., Jonsson, K.-O., & Fowler, C. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023370707 · Cited by 299
Challenges in Using Opioids to Treat Pain in Persons With Substance Use Disorders
Savage, S., Kirsh, K., & Passik, S. (2008) · Addiction Science & Clinical Practice · doi:10.1151/ascp08424 · Cited by 292
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S.-R., Willenbring, D., Guan, Y., Pan, H.-L., Ren, K., Xu, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120242 · Cited by 288
Wade, D. T., Makela, P. M., House, H., Bateman, C., & Robson, P. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458505070618 · Cited by 285
Cannabis and Pain: A Clinical Review
Hill, K. P., Palastro, M. D., Johnson, B., & Ditre, J. W. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0017 · Cited by 281
Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy
Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., & Atkinson, J. H. (2015) · The Journal of Pain · doi:10.1016/j.jpain.2015.03.008 · Cited by 276
Ward, S. J., McAllister, S. D., Kawamura, R., Murase, R., Neelakantan, H., & Walker, E. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12439 · Cited by 276
Marijuana Dependence and Its Treatment
Budney, A., Roffman, R., Stephens, R., & Walker, D. (2007) · Addiction Science & Clinical Practice · doi:10.1151/ascp07414 · Cited by 275
Analgesic Effect of Delta‐9‐Tetrahydrocannabinol
NOYES, R., BRUNK, S. F., BARAM, D. A., & CANTER, A. (1975) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1975.tb02348.x · Cited by 273
Lucas, P., & Walsh, Z. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.01.011 · Cited by 271
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
The cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 267
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data
Andreae, M. H., Carter, G. M., Shaparin, N., Suslov, K., Ellis, R. J., Ware, M. A., Abrams, D. I., Prasad, H., Wilsey, B., Indyk, D., et al. (2015) · The Journal of Pain · doi:10.1016/j.jpain.2015.07.009 · Cited by 266
Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis
Nielsen, S., Sabioni, P., Trigo, J. M., Ware, M. A., Betz-Stablein, B. D., Murnion, B., Lintzeris, N., Khor, K. E., Farrell, M., Smith, A., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.51 · Cited by 265
A systematic review of the antipsychotic properties of cannabidiol in humans
Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261
The health and social effects of nonmedical cannabis use.
Hall, W., Renstrom, M., & Poznyak, V. B. (2016) · Cited by 261
CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
Dhopeshwarkar, A., & Mackie, K. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094649 · Cited by 257
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
Ware, M. A., Wang, T., Shapiro, S., Collet, J.-P., Boulanger, A., Esdaile, J. M., Gordon, A., Lynch, M., Moulin, D. E., & O'Connell, C. (2015) · The Journal of Pain · doi:10.1016/j.jpain.2015.07.014 · Cited by 249
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
Clayton, N., Marshall, F. H., Bountra, C., & O'Shaughnessy, C. T. (2002) · Pain · doi:10.1016/s0304-3959(01)00454-7 · Cited by 247
Peripheral gating of pain signals by endogenous lipid mediators
Piomelli, D., & Sasso, O. (2014) · Nature Neuroscience · doi:10.1038/nn.3612 · Cited by 246
The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors
Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.022 · Cited by 246
Inhibition of Inflammatory Hyperalgesia by Activation of Peripheral CB2Cannabinoid Receptors
Quartilho, A., Mata, H. P., Ibrahim, M. M., Vanderah, T. W., Porreca, F., Makriyannis, A., & Malan, T. P. (2003) · Anesthesiology · doi:10.1097/00000542-200310000-00031 · Cited by 242
Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs
Olesen, A. E., Andresen, T., Staahl, C., & Drewes, A. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005447 · Cited by 239
Johnson, J. R., Lossignol, D., Burnell-Nugent, M., & Fallon, M. T. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.07.014 · Cited by 236
Ahn, K., Smith, S. E., Liimatta, M. B., Beidler, D., Sadagopan, N., Dudley, D. T., Young, T., Wren, P., Zhang, Y., Swaney, S., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180257 · Cited by 230
Cannabinoid activation of PPARα; a novel neuroprotective mechanism
Sun, Y., Alexander, S. P. H., Garle, M. J., Gibson, C. L., Hewitt, K., Murphy, S. P., Kendall, D. A., & Bennett, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707478 · Cited by 229
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats
Petrosino, S., Palazzo, E., de Novellis, V., Bisogno, T., Rossi, F., Maione, S., & Di Marzo, V. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.011 · Cited by 227
Chanda, P. K., Gao, Y., Mark, L., Btesh, J., Strassle, B. W., Lu, P., Piesla, M. J., Zhang, M.-Y., Bingham, B., Uveges, A., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068304 · Cited by 226
Colorado Family Physicians' Attitudes Toward Medical Marijuana
Kondrad, E., & Reid, A. (2013) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2013.01.120089 · Cited by 221
Abrams, D., & Guzman, M. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.108 · Cited by 219
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain
Anand, P., Whiteside, G., Fowler, C. J., & Hohmann, A. G. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.003 · Cited by 218
Cannabinoid CB 1 and CB 2 Receptor Signaling and Bias
Ibsen, M. S., Connor, M., & Glass, M. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0037 · Cited by 217
Barann, M., Molderings, G., Brüss, M., Bönisch, H., Urban, B. W., & Göthert, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704829 · Cited by 215
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal
Scavone, J. L., Sterling, R. C., & Van Bockstaele, E. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.034 · Cited by 209
Mitrirattanakul, S., Ramakul, N., Guerrero, A. V., Matsuka, Y., Ono, T., Iwase, H., Mackie, K., Faull, K. F., & Spigelman, I. (2006) · Pain · doi:10.1016/j.pain.2006.06.016 · Cited by 207
Deng, L., Guindon, J., Cornett, B. L., Makriyannis, A., Mackie, K., & Hohmann, A. G. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.009 · Cited by 204
Maione, S., De Petrocellis, L., de Novellis, V, Moriello, A. S., Petrosino, S., Palazzo, E., Rossi, F. S., Woodward, D. F., & Di Marzo, V (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707145 · Cited by 196
Lynch, M. E., & Ware, M. A. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9600-6 · Cited by 195
Lim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195
Cannabinoids and Pain: Sites and Mechanisms of Action
Starowicz, K., & Finn, D. P. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.05.003 · Cited by 193
Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep
Piper, B. J., DeKeuster, R. M., Beals, M. L., Cobb, C. M., Burchman, C. A., Perkinson, L., Lynn, S. T., Nichols, S. D., & Abess, A. T. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699616 · Cited by 190
ROG, D., NURMIKKO, T., & YOUNG, C. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.013 · Cited by 187 · cited 1×
“The safety and tolerability of nabiximols long-term use in different conditions (cancer pain, spasticity and neuropathic pain in MS patients) has been studied in a series of trials of up to 2 years duration (Wade et al., 2006; Rog et al., 2007; Johnson et al., 2013; Serpell et al., 2013).”
BackgroundThe major central endocannabinoid directly acts at GABAAreceptors
Sigel, E., Baur, R., Rácz, I., Marazzi, J., Smart, T. G., Zimmer, A., & Gertsch, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113444108 · Cited by 186
Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain
Buggy, D. J., Toogood, L., Maric, S., Sharpe, P., Lambert, D. G., & Rowbotham, D. J. (2003) · Pain · doi:10.1016/s0304-3959(03)00331-2 · Cited by 184
Spinal Endocannabinoids and CB 1 Receptors Mediate C-Fiber–Induced Heterosynaptic Pain Sensitization
Pernía-Andrade, A. J., Kato, A., Witschi, R., Nyilas, R., Katona, I., Freund, T. F., Watanabe, M., Filitz, J., Koppert, W., Schüttler, J., et al. (2009) · Science · doi:10.1126/science.1171870 · Cited by 184
Fallon, M. T., Albert Lux, E., McQuade, R., Rossetti, S., Sanchez, R., Sun, W., Wright, S., Lichtman, A. H., & Kornyeyeva, E. (2017) · British Journal of Pain · doi:10.1177/2049463717710042 · Cited by 181
Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis
Meng, H., Johnston, B., Englesakis, M., Moulin, D. E., & Bhatia, A. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002110 · Cited by 169
Holdcroft, A., Maze, M., Doré, C., Tebbs, S., & Thompson, S. (2006) · Anesthesiology · doi:10.1097/00000542-200605000-00021 · Cited by 166
Effects of nabilone, a synthetic cannabinoid, on postoperative pain
Beaulieu, P. (2006) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/bf03022793 · Cited by 161
Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia
Xiong, W., Cheng, K., Cui, T., Godlewski, G., Rice, K. C., Xu, Y., & Zhang, L. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.552 · Cited by 161
Elmes, S. J. R., Jhaveri, M. D., Smart, D., Kendall, D. A., & Chapman, V. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03690.x · Cited by 160
Toth, C. C., Jedrzejewski, N. M., Ellis, C. L., & Frey, W. H. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-16 · Cited by 160
Atwood, B. K., Wager‐Miller, J., Haskins, C. P., Straiker, A. J., & Mackie, K. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074013 · Cited by 160
Fitzcharles, M., Baerwald, C., Ablin, J. N., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0084-3 · Cited by 159
Hejazi, N. S., Zhou, C., Öz, M., Sun, H., Ye, J. H., & Zhang, L. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.019174 · Cited by 158
Ahrens, J., Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., Karst, M., & Haeseler, G. (2009) · Pharmacology · doi:10.1159/000201556 · Cited by 154
Rahn, E. J., Makriyannis, A., & Hohmann, A. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707333 · Cited by 146
Lomazzo, E., Bîndilă, L., Remmers, F., Lerner, R., Schwitter, C., Hoheisel, U., & Lutz, B. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.198 · Cited by 143
Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia
Kaczocha, M., Rebecchi, M. J., Ralph, B. P., Teng, Y.-H. G., Berger, W. T., Galbavy, W., Elmes, M. W., Glaser, S. T., Wang, L., Rizzo, R. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094200 · Cited by 142
Hsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139
Slivicki, R. A., Xu, Z., Kulkarni, P. M., Pertwee, R. G., Mackie, K., Thakur, G. A., & Hohmann, A. G. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.032 · Cited by 139
Interferon-γ Is a Critical Modulator of CB2Cannabinoid Receptor Signaling during Neuropathic Pain
Rácz, I., Nadal, X., Alferink, J., Baños, J.-E., Rehnelt, J., Martín, M., Pintado, B., Gutiérrez‐Adán, A., Sanguino, E., Bellora, N., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3402-08.2008 · Cited by 136
Control of synaptic function by endocannabinoid-mediated retrograde signaling
Kano, M. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.235 · Cited by 135
Sumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., Mechoulam, R., & Feldmann, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20050 · Cited by 134
The neurobiology of cannabinoid analgesia
Walker, J. M., Hohmann, A. G., Martin, W. J., Strangman, N. M., Huang, S. M., & Tsou, K. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00289-1 · Cited by 134
Boychuk, D., Goddard, G., Mauro, G., & Orellana, M. (2015) · Journal of Oral & Facial Pain and Headache · doi:10.11607/ofph.1274 · Cited by 130
Kraft, B., Frickey, N., Kaufmann, R. M., Reif, M., Frey, R., Gustorff, B., & Kress, H. G. (2008) · Anesthesiology · doi:10.1097/aln.0b013e31817881e1 · Cited by 130
Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy
Khasabova, I. A., Khasabov, S., Paz, J., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0403-12.2012 · Cited by 129
Ignatowska‐Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J., Abdullah, R. A., Tao, Q., O' Neal, S. T., Walentiny, D. M., Wiley, J. L., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12298 · Cited by 128
More surprises lying ahead. The endocannabinoids keep us guessing
Piomelli, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.026 · Cited by 128
Biomarkers for the effects of cannabis and THC in healthy volunteers
Zuurman, L., Ippel, A. E., Moin, E., & van Gerven, J. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03329.x · Cited by 127
Ostenfeld, T., Price, J. A., Albanese, M., Bullman, J., Guillard, F., Meyer, I., Leeson, R., Costantin, C., Ziviani, L., Nocini, P. F., et al. (2011) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318219799a · Cited by 126
Kiritoshi, T., Ji, G., & Neugebauer, V. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4047-15.2016 · Cited by 125
Schlosburg, J. E., Carlson, B. L. A., Ramesh, D., Abdullah, R. A., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9110-7 · Cited by 121
Cannabis and Cannabinoids for Chronic Pain
Romero-Sandoval, E. A., Kolano, A. L., & Alvarado-Vazquez, P. A. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0693-1 · Cited by 121
Kinsey, S. G., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.04.001 · Cited by 118
A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats
Pascual, D., Goicoechea, C., Suardíaz, M., & Martín, M. I. (2005) · Pain · doi:10.1016/j.pain.2005.07.008 · Cited by 117
Booker, L., Kinsey, S. G., Abdullah, R. A., Blankman, J. L., Long, J. Z., Ezzili, C., Boger, D. L., Cravatt, B. F., & Lichtman, A. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01445.x · Cited by 116
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
Serpell, M. G., Notcutt, W. G., & Collin, C. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6634-z · Cited by 116
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations
Gewandter, J. S., Dworkin, R. H., Turk, D. C., McDermott, M. P., Baron, R., Gastonguay, M. R., Gilron, I., Katz, N. P., Mehta, C. R., Raja, S. N., et al. (2014) · Pain · doi:10.1016/j.pain.2014.05.025 · Cited by 114
Retrograde Signalling by Endocannabinoids
Vaughan, C. W., & Christie, M. J. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_12 · Cited by 113
Rationale for cannabis-based interventions in the opioid overdose crisis
Lucas, P. (2017) · Harm Reduction Journal · doi:10.1186/s12954-017-0183-9 · Cited by 112
Adverse Health Effects of Marijuana Use
Volkow, N. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1407928 · Cited by 110
The search for novel analgesics: targets and mechanisms
Yaksh, T. L., Woller, S. A., Ramachandran, R., & Sorkin, L. S. (2015) · F1000Prime Reports · doi:10.12703/p7-56 · Cited by 104
Giordano, C., Cristino, L., Luongo, L., Siniscalco, D., Petrosino, S., Piscitelli, F., Marabese, I., Gatta, L., Rossi, F., Imperatore, R., et al. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr328 · Cited by 104
Comelli, F., Giagnoni, G., Bettoni, I., Colleoni, M., & Costa, B. (2008) · Phytotherapy Research · doi:10.1002/ptr.2401 · Cited by 103
Yu, X. H., Cao, C. Q., Martino, G., Puma, C., Morinville, A., St-Onge, S., Lessard, É., Perkins, M., & Laird, J. M. A. (2010) · Pain · doi:10.1016/j.pain.2010.07.019 · Cited by 103
Hwang, J., Adamson, C. L., Butler, D., Janero, D. R., Makriyannis, A., & Bahr, B. A. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.06.003 · Cited by 100
Wilkerson, J. L., Gentry, K. R., Dengler, E. C., Wallace, J. A., Kerwin, A. A., Armijo, L. M., Kuhn, M. N., Thakur, G. A., Makriyannis, A., & Milligan, E. D. (2012) · Pain · doi:10.1016/j.pain.2012.02.015 · Cited by 100
Belendiuk, K. A., Baldini, L., & Bonn‐Miller, M. O. (2015) · Addiction Science & Clinical Practice · doi:10.1186/s13722-015-0032-7 · Cited by 100
Medical cannabis ‒ the Canadian perspective
Ramkellawan, S., Bober, S., Mindra, S., Moreau, J. M., & Ko, G. D. (2016) · Journal of Pain Research · doi:10.2147/jpr.s98182 · Cited by 100
Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain
Porta, C. L., Bura, S. A., Llorente‐Onaindia, J., Pastor, A., Navarrete, F., García‐Gutiérrez, M. S., de la Torre, R., Manzanares, J., Monfort, J., & Maldonado, R. J. (2015) · Pain · doi:10.1097/j.pain.0000000000000260 · Cited by 98
Kinsey, S. G., Mahadevan, A., Zhao, B., Sun, H., Naidu, P. S., Razdan, R. K., Selley, D. E., Damaj, M. I., & Lichtman, A. H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.09.004 · Cited by 97
Elmes, S. J. R., Winyard, L. A., Medhurst, S. J., Clayton, N. M., Wilson, A. W., Kendall, D. A., & Chapman, V. (2005) · Pain · doi:10.1016/j.pain.2005.09.005 · Cited by 97
de Vries, M., van Rijckevorsel, D. C., Vissers, K. C. P., Wilder‐Smith, O. H. G., & van Goor, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.09.147 · Cited by 95
Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis
Fukuda, S., Kohsaka, H., Takayasu, A., Yokoyama, W., Miyabe, C., Miyabe, Y., Harigai, M., Miyasaka, N., & Nanki, T. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-275 · Cited by 93
Medical Consequences of Marijuana Use: A Review of Current Literature
Gordon, A. J., Conley, J. W., & Gordon, J. M. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0419-7 · Cited by 93
Khasabova, I. A., Khasabov, S. G., Harding-Rose, C., Coicou, L. G., Seybold, B., Lindberg, A. E., Steevens, C. D., Simone, D. A., & Seybold, V. S. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2847-08.2008 · Cited by 91
Sagar, D. R., Kendall, D. A., & Chapman, V. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.335 · Cited by 90
Yamamoto, W., Mikami, T., & Iwamura, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.010 · Cited by 89
Kaur, R., Sidhu, P., & Singh, S. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.189661 · Cited by 89
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
Roche, M., & Finn, D. P. (2010) · Pharmaceuticals · doi:10.3390/ph3082517 · Cited by 88
Rockwell, C. E., & Kaminski, N. E. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065524 · Cited by 86
(2008) · PubMed · Cited by 82
Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis
Lowin, T., & Straub, R. H. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0743-x · Cited by 82
Starowicz, K., Makuch, W., Osikowicz, M., Piscitelli, F., Petrosino, S., Marzo, V. D., & Przewłocka, B. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.021 · Cited by 80
Khurana, L., Mackie, K., Piomelli, D., & Kendall, D. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.018 · Cited by 80
Niu, J., Huang, D., Zhou, R., Yue, M.-X., Xu, T., Yang, J., Li, H., Tian, H. W., Liu, X., & Zeng, J. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0960-0 · Cited by 78
The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level
Horváth, G., Kékesi, G., Nagy, E., & Benedek, G. (2007) · Pain · doi:10.1016/j.pain.2007.04.032 · Cited by 77
Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells
Small-Howard, A. L., Shimoda, L. M. N., Adra, C. N., & Turner, H. C. (2005) · Biochemical Journal · doi:10.1042/bj20041682 · Cited by 77
Rong, C., Carmona, N. E., Lee, Y. L., Ragguett, R., Pan, Z., Rosenblat, J. D., Subramaniapillai, M., Shekotikhina, M., Almatham, F., Alageel, A. A. S., et al. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1397128 · Cited by 73
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model
Barnes, N. S. A., Mitchell, V. A., Kazantzis, N. P., & Vaughan, C. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13337 · Cited by 72
Schuelert, N., Johnson, M. P., Oskins, J. L., Jassal, K., Chambers, M. G., & McDougall, J. J. (2011) · Pain · doi:10.1016/j.pain.2010.11.025 · Cited by 70
Vincent, L., Vang, D., Nguyen, J., Benson, B. A., Lei, J.-X., & Gupta, K. (2015) · Haematologica · doi:10.3324/haematol.2015.136523 · Cited by 70
Caprioli, A., Coccurello, R., Rapino, C., Serio, S. D., Tommaso, M. D., Vertechy, M., Vacca, V., Battista, N., Pavone, F., Maccarrone, M., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191403 · Cited by 69
Liang, Y.-C., Huang, C.-C., & Hsu, K.-S. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.04.019 · Cited by 68
Fentanyl Analogs: Structure-Activity-Relationship Study
Vuckovic, S. M., Prostran, M. S., Ivanović, M., Došen‐Mićović, L., Todorović, Z., Nesic, Z., Stojanovic, R., Divac, N., & Miković, Ž. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788682074 · Cited by 68
Self-citationFichna, J., Sałaga, M., Stuart, J. M., Saur, D., Sobczak, M., Zatorski, H., Timmermans, J., Bradshaw, H. B., Ahn, K., & Storr, M. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12272 · Cited by 64
Sasso, O., Migliore, M., Habrant, D., Armirotti, A., Albani, C., Summa, M., Moreno‐Sanz, G., Scarpelli, R., & Piomelli, D. (2015) · The FASEB Journal · doi:10.1096/fj.15-270637 · Cited by 63
Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system
Starowicz, K., & Przewłocka, B. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0392 · Cited by 62
Burgos, E., Pascual, D., Martín, M. I., & Goicoechea, C. (2009) · European Journal of Pain · doi:10.1016/j.ejpain.2009.02.003 · Cited by 61
Gui, H., Liu, X., Liu, L.-R., Su, D.-F., & Dai, S.-M. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.12.012 · Cited by 60
Magnesium in Pain Research: State of the Art
Prostran, M. S., Vujović, K. S., Kosutic, J. L., Milovanović, A., Vuckovic, S. M., & Srebro, D. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666161213101744 · Cited by 59
Self-citationAntiepileptic drugs as analgesics/adjuvants in inflammatory pain: current preclinical evidence
Tomic´, M. A., Pecikoza, U. B., Micov, A. M., Vučković, S., & Stepanović-Petrović, R. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.002 · Cited by 59
Self-citationCB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain
Khasabova, I. A., Gielissen, J. M., Chandiramani, A., Harding-Rose, C., Odeh, D. A., Simone, D. A., & Seybold, V. S. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283474a6d · Cited by 55
A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis
Jawahar, R., Oh, U., Yang, S., & Lapane, K. L. (2013) · Drugs · doi:10.1007/s40265-013-0125-0 · Cited by 55
Medicinal cannabis: rational guidelines for dosing.
Carter, G. T., Weydt, P., Kyashna-Tocha, M., & Abrams, D. I. (2004) · PubMed · Cited by 54
A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase
Carey, L. M., Slivicki, R. A., Leishman, E., Cornett, B., Mackie, K., Bradshaw, H. B., & Hohmann, A. G. (2016) · Molecular Pain · doi:10.1177/1744806916649192 · Cited by 54
Wilsey, B. L., Deutsch, R., Samara, E. E., Marcotte, T. D., Barnes, A. J., Huestis, M. A., & Le, D. (2016) · Journal of Pain Research · doi:10.2147/jpr.s113138 · Cited by 52
Małek, N., & Starowicz, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00257 · Cited by 51
Grim, T. W., Ghosh, S., Hsu, K.-L., Cravatt, B. F., Kinsey, S. G., & Lichtman, A. H. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.07.008 · Cited by 50
Pawsey, S., Wood, M., Browne, H. L., Donaldson, K. M., Christie, M. I., & Warrington, S. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0127-y · Cited by 50
Issa, M., Narang, S., Jamison, R. N., Michna, E., Edwards, R. R., Penetar, D. M., & Wasan, A. D. (2013) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000022 · Cited by 48
Peripheral cannabinoids attenuate carcinoma-induced nociception in mice
Guerrero, A. V., Quang, P. N., Dekker, N. P., Jordan, R. C., & Schmidt, B. L. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2007.12.053 · Cited by 48
Cited by
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Cardiovascular Effects of Cannabinoids
Wang, A., Dey, S., Subhan, S., Patel, J., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000566 · Cited by 6
Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-03152 · Cited by 4
Metadata
- Authors
- Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-13
- Volume
- 9
- Pages
- 1259-1259
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2901552564
- Cited by
- 376
- References
- 213
- FWCI
- 15.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.